S
Suzanne Oparil
Researcher at University of Alabama at Birmingham
Publications - 941
Citations - 122414
Suzanne Oparil is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Blood pressure & Angiotensin II. The author has an hindex of 106, co-authored 885 publications receiving 113983 citations. Previous affiliations of Suzanne Oparil include Michigan State University & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
Neuronal angiotensin-converting enzyme (ACE) gene expression is increased by converting enzyme inhibitors (CEI)
TL;DR: The conclusions that the activity of the brain renin angiotensin system is enhanced in SHR and that blockade of this system by chronic ACE inhibitor treatment contributes to the sustained antihypertensive effect of ACE inhibitors in this model are supported.
Journal ArticleDOI
Regression of Left Ventricular Mass After Bariatric Surgery
TL;DR: Three-dimensional (3D) echocardiography may obviate the limitations of M-mode 2D echOCardiography for assessment of LV mass and allow an accurate appraisal of the effects of bariatric surgery on LV mass.
Journal ArticleDOI
Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial).
Brian P. Shapiro,Walter T. Ambrosius,Joseph L. Blackshear,William C. Cushman,Paul K. Whelton,Suzanne Oparil,Srinivasan Beddhu,Jamie P. Dwyer,Lisa H. Gren,William J. Kostis,Michael Lioudis,Roberto Pisoni,Clive Rosendorff,William E. Haley +13 more
TL;DR: Findings from SPRINT add support for clinicians to treat blood pressure to goal irrespective of baseline SBP, as the beneficial effects of intensive SBP lowering were not modified by the level of baselineSBP.
Journal ArticleDOI
The neointimal response to endovascular injury is increased in obese Zucker rats
TL;DR: Restenosis after revascularization procedures is accelerated in persons with type 2 diabetes, and the risk of heart attack and stroke is increased.
Journal ArticleDOI
A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension
Suzanne Oparil,Nicola Abate,Erluo Chen,Mark A. Creager,Vincent A. Galet,Gang Jia,Stevo Julius,A. Lerman,Paulette A. Lyle,James L. Pool,Andrew M. Tershakovec +10 more
TL;DR: It is concluded that losartan alone or in combination with HCTZ was generally well tolerated and effective in the treatment of elevated systolic and diastolic BP in obese patients with hypertension.